According to section 2.3.7 of the Nasdaq First North Growth Market Rulebook, an issuer shall be able to demonstrate ongoing business operations.
According to section 8.2.7 of the Nasdaq First North Growth Market Rulebook, the Exchange may decide to remove an issuer's financial instruments from trading if the issuer materially no longer meets the applicable listing requirements.
On February 16, 2026, Lipigon Pharmaceuticals AB (the "Company") disclosed information that that the Company's most advanced drug candidate, Lipisense, had not demonstrated clinically relevant results in the phase 2 study. The press release also stated that in-depth analyses had confirmed this outcome and that there is uncertainty regarding the Company's continued financing and operations. It further stated that, despite cost-saving measures, the Company has limited cash resources and is dependent on securing additional financing or carrying out a strategic transaction in order to continue its operations. Nasdaq Stockholm AB considers that since then, the Company has not met the listing requirement in section 2.3.7 to demonstrate ongoing business operations and that the deficiency in meeting the listing requirement is material.
With reference to the above, Nasdaq Stockholm AB has decided to remove the shares of the Company from trading on Nasdaq First North Growth Market.
| Company registration number | 556810-9077 |
| Short name: | LPGO |
| ISIN code: | SE0015382072 |
| Order book ID: | 216630 |
The last day of trading on Nasdaq First North Growth Market will be May 18, 2026.
For further information regarding this exchange notice please contact Enforcement & Investigations, telephone + 46 8 405 70 50.
Nasdaq Stockholm AB
